Stay up to date with the latest news and announcements from NASCSA.
The US Drug Enforcement Administration (DEA) has reached out the National Association of State Controlled Substances Authorities (NASCSA) to seek the assistance of state Prescription Monitoring Programs in establishing aggregate production quotas (APQs) for certain drugs as required by Congress.
The Drug Enforcement Administration (DEA) is required under the Controlled Substances Act (CSA) to establish aggregate production quotas (APQ) for each basic class of controlled substance in schedules I and II, and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. Since 2021, NASCSA has played a pivotal role in DEA?s ability to comply with these statutory requirements. It is requested that State PDMP Administrators utilize the analytic tool provided by Bamboo Health to run the 2022 Aggregate Production Quota Report. Bamboo Health will provide assistance to states regarding questions related to report calculations and specifications. Please contact APQReport@BambooHealth.com. DEA would appreciate receiving responses from State PDMP Administrators no later than June 1, 2023, so the data may be considered in establishing the 2024 APQs. The reports and or any questions may be emailed to: firstname.lastname@example.org and email@example.com. A direct request from the DEA will soon follow.